Last reviewed · How we verify
Moderate to severe ulcerative colitis and perianal disease and fistulizing disease
Approved treatments
- Induction- PF-06480605 450 mg SC Q4W · Pfizer
PF-06480605 is a small molecule that targets the IL-17 pathway to treat inflammatory conditions.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Moderate to severe ulcerative colitis and perianal disease and fistulizing disease patent landscape — cliff calendar, originator estates, attackable patents
- Moderate to severe ulcerative colitis and perianal disease and fistulizing disease treatment landscape brief
- Moderate to severe ulcerative colitis and perianal disease and fistulizing disease treatment updates RSS
Frequently asked questions about Moderate to severe ulcerative colitis and perianal disease and fistulizing disease
What drugs treat Moderate to severe ulcerative colitis and perianal disease and fistulizing disease?
Tracked treatments include Induction- PF-06480605 450 mg SC Q4W.
What is the treatment for Moderate to severe ulcerative colitis and perianal disease and fistulizing disease?
Standard treatment for Moderate to severe ulcerative colitis and perianal disease and fistulizing disease includes Induction- PF-06480605 450 mg SC Q4W. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Moderate to severe ulcerative colitis and perianal disease and fistulizing disease patent cliff · Moderate to severe ulcerative colitis and perianal disease and fistulizing disease CI report
- Treatment: Induction- PF-06480605 450 mg SC Q4W · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing